| 发明名称 | Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid | ||
| 摘要 | The present invention relates to novel crystal forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid. More particularly, the invention relates to polymorph forms (Polymorph Form I or Polymorph Form II), and to processes for the preparation of, compositions containing and to uses of, such polymorph forms. | ||
| 申请公布号 | US9187463(B2) | 申请公布日期 | 2015.11.17 |
| 申请号 | US201214118377 | 申请日期 | 2012.05.18 |
| 申请人 | RAQUALIA PHARMA INC. | 发明人 | Numata Toyoharu;Noguchi Hirohide;Waizumi Nobuaki;Kojima Takashi |
| 分类号 | C07D413/14 | 主分类号 | C07D413/14 |
| 代理机构 | Marshall, Gerstein & Borun LLP | 代理人 | Marshall, Gerstein & Borun LLP |
| 主权项 | 1. 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid Polymorph Form I, which is characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-Kα radiation which includes main peaks at 2-Theta° 5.9, 9.3, 9.8, 11.9, 13.7, 14.3, 15.0, 17.8, 18.2-19.3, 19.7, 22.6, 23.4-24.5 and 24.9+/−0.2. | ||
| 地址 | Aichi JP | ||